The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
124576033 12457603 3 F 20160322 20160817 20160610 20160826 EXP GB-BAUSCH-BL-2016-013543 BAUSCH AND LOMB 75.00 YR M Y 99.00000 KG 20160826 MD GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
124576033 12457603 1 PS PREDNISOLONE. PREDNISOLONE 1 Oral 40070 130 MG
124576033 12457603 2 SS MELPHALAN MELPHALAN 1 Oral 0 20 MG
124576033 12457603 3 SS VELCADE BORTEZOMIB 1 Subcutaneous V15541-09,1537301,1537302 0 2.75 MG LYOPHILIZED POWDER
124576033 12457603 4 C RAMIPRIL. RAMIPRIL 1 Oral 0 5 MG QD
124576033 12457603 5 C RANITIDINE. RANITIDINE 1 Oral 0 150 MG BID
124576033 12457603 6 C ZOLEDRONIC ACID ZOLEDRONIC ACID 1 Intravenous (not otherwise specified) 0 4 MG /month
124576033 12457603 7 C ACICLOVIR ACYCLOVIR 1 Oral 0 200 MG QID
124576033 12457603 8 C METOCLOPRAMIDE. METOCLOPRAMIDE 1 Oral 1/1 AS NECESSARY 0 10 MG
124576033 12457603 9 C METOCLOPRAMIDE. METOCLOPRAMIDE 1 0
124576033 12457603 10 C ATORVASTATIN ATORVASTATIN 1 Oral 0 5 MG QD
124576033 12457603 11 C ALLOPURINOL. ALLOPURINOL 1 Oral 0 300 MG QD
124576033 12457603 12 C LOPERAMIDE LOPERAMIDE 1 Oral 1/1 AS NECESSARY 0 2 MG
124576033 12457603 13 C COCODAMOL ACETAMINOPHENCODEINE PHOSPHATE 1 Oral 1 / 1 AS NECESSARY 0 2 DF
124576033 12457603 14 C DOXAZOSIN DOXAZOSINDOXAZOSIN MESYLATE 1 Oral 0 4 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
124576033 12457603 1 Plasma cell myeloma
124576033 12457603 2 Plasma cell myeloma
124576033 12457603 3 Plasma cell myeloma
124576033 12457603 4 Hypertension
124576033 12457603 5 Prophylaxis
124576033 12457603 6 Prophylaxis
124576033 12457603 7 Antiviral prophylaxis
124576033 12457603 8 Prophylaxis of nausea and vomiting
124576033 12457603 9 Prophylaxis of nausea and vomiting
124576033 12457603 10 Hypertension
124576033 12457603 11 Prophylaxis
124576033 12457603 12 Diarrhoea
124576033 12457603 13 Pain
124576033 12457603 14 Hypertension

Outcome of event

Event ID CASEID OUTC COD
124576033 12457603 OT
124576033 12457603 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
124576033 12457603 Diarrhoea
124576033 12457603 Eye infection
124576033 12457603 Herpes zoster
124576033 12457603 Neutrophil count decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
124576033 12457603 1 20160318 20160321 0
124576033 12457603 2 20160318 20160321 0
124576033 12457603 3 20160318 20160328 0
124576033 12457603 5 20160318 0
124576033 12457603 6 20160321 0
124576033 12457603 7 20160318 20160407 0
124576033 12457603 8 20160318 0
124576033 12457603 11 20160318 20160428 0
124576033 12457603 12 20160322 20160324 0